Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
Recruiting
Phase 4
Interventional Study
Coronary Arterial Disease (CAD)
Vulnerable Coronary Plaques
Thin-cap fIbroatheroma
Acute Coronary Syndromes (ACS)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 2,190 (estimated)
- Sponsor
- Beijing Anzhen Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this clinical trial is to explore the optimal preventative treatment strategy for non-flow-limiting vulnerable plaques. The main question it aims to answer is:
Can interventional therapy further improve the outcome of non-flow-limiting vulnerable plaques on top of optimal pharmacologic therapy?
Researchers will randomly assign patients who meet the inclusion criteria to preventative i…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria Clinical Inclusion Criteria 1. Males or non-pregnant females aged 18-80 years 2. Clinically diagnosed with acute coronary syndrome (including unstable angina, ST-segment elevation myocardial infarction, and non-ST-segment elevation myocardial infarction) 3. Patients willing and ab…
Contacts